RESATA

UNIVADIS - RESATA /univadis/RESATA.md

ATC

Μορφές: M.D.NAS.SP
Μορφές: INH.PD.DOS
Μορφές:

Δραστικές

Δελτίο Τιμών 05/2018

Ημερομηνία barcode code περιεχομενο τιμή παραγωγός χονδρική λιανική
05/2018 2802338301013 233830101 RESATA M.D.NAS.SP 100MCG/DOSE FLX10ML(200DOSES) 6.69 07.02 9.67
05/2018 2803072001016 307200101 RESATA NEB INH.SUS.N 0,25MG/ML BTx20 AMPS 4.16 4.36 06.01
05/2018 2803072002013 307200201 RESATA NEB INH.SUS.N 0,5MG/ML BTx20 AMPS 5.85 6.14 8.46
  • DRUGBANK - Budesonide
  • indication:

    For the treatment of mild to moderate active Crohn's disease. Also for the treatment of asthma, non-infectious rhinitis (including hay fever and other allergies), and for treatment and prevention of nasal polyposis.

  • pharmacology:

  • mechanism:

    The exact mechanism of action of budesonide in the treatment of Crohn's disease is not fully understood. However, being a glucocorticosteroid, budesonide has a high local anti-inflammatory effect.

  • toxicity:

    Single oral doses of 200 and 400 mg/kg were lethal in female and male mice, respectively. The signs of acute toxicity were decreased motor activity, piloerection and generalized edema.

  • absorprion:

    Absorption is complete following oral administration.

  • halflife:

    2.0 and 3.6 hours

  • roouteelimination:

    Budesonide is excreted in urine and feces in the form of metabolites.

  • volumedistribution:

    * 3 L/kg [asthmatic children 4 to 6 years of age]

  • clearance:

    * 0.5 L/min [Athmatic children 4 to 6 years of age]